“…From a view point of drug design for antioxidant therapy, much effort has been directed for decades toward development of organoselenium compounds [ 2 , 3 , 4 , 5 , 6 , 7 ], which can act as GPx-like catalysts, and also toward elucidation of their catalytic mechanisms [ 8 , 9 , 10 , 11 ]. Various GPx model compounds, most of which are aromatic diselenides (ArSeSeAr), have been developed and their catalytic activities have been evaluated [ 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 ]. In the meantime, aliphatic and/or aromatic monoselenides (RSeR′) are also known to act as GPx-like catalysts through a unique selenide/selenoxide redox cycle ( Scheme 1 , cycle A), in which selenide 1 is oxidized by H 2 O 2 to the corresponding selenoxide 2 , which is reduced back to 1 by a thiol substrate (RSH) [ 26 , 27 , 28 , 29 ].…”